Sarepta cites 'overburdened' FDA as factor in DMD gene therapy delay

Sarepta cites 'overburdened' FDA as factor in DMD gene therapy delay

Submitted by admin on September 11, 2020 - 10:55am
Source: 
Fierce Biotech
News Tags: 
Sarepta Therapeutics
Duchenne Muscular Dystrophy
gene therapy
FDA
Headline: 
Sarepta cites 'overburdened' FDA as factor in DMD gene therapy delay
snippet: 

Burdens placed on the FDA by COVID-19 and the rapid proliferation of cell and gene therapies are a factor in the recent setback to Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) prospect, according to CEO Douglas Ingram.

Do Not Allow Advertisers to Use My Personal information